GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Beneish M-Score

Xvivo Perfusion AB (Xvivo Perfusion AB) Beneish M-Score : -2.06 (As of May. 02, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Xvivo Perfusion AB's Beneish M-Score or its related term are showing as below:

XVIPF' s Beneish M-Score Range Over the Past 10 Years
Min: -2.87   Med: -2.31   Max: -1.21
Current: -2.06

During the past 12 years, the highest Beneish M-Score of Xvivo Perfusion AB was -1.21. The lowest was -2.87. And the median was -2.31.


Xvivo Perfusion AB Beneish M-Score Historical Data

The historical data trend for Xvivo Perfusion AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Beneish M-Score Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.65 -2.67 -2.06 -1.91 -2.25

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.80 -2.31 -2.34 -2.25 -2.06

Competitive Comparison of Xvivo Perfusion AB's Beneish M-Score

For the Medical Devices subindustry, Xvivo Perfusion AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Beneish M-Score falls into.



Xvivo Perfusion AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Xvivo Perfusion AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.938+0.528 * 0.9824+0.404 * 0.8207+0.892 * 1.3666+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9568+4.679 * 0.018871-0.327 * 0.579
=-2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $16.19 Mil.
Revenue was 17.867 + 15.183 + 13.227 + 14.353 = $60.63 Mil.
Gross Profit was 12.977 + 11.429 + 9.707 + 10.722 = $44.84 Mil.
Total Current Assets was $79.79 Mil.
Total Assets was $216.47 Mil.
Property, Plant and Equipment(Net PPE) was $10.58 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $30.89 Mil.
Total Current Liabilities was $19.19 Mil.
Long-Term Debt & Capital Lease Obligation was $1.91 Mil.
Net Income was 2.188 + 6.675 + 0.206 + 0.639 = $9.71 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was 0.153 + 1.767 + 2.241 + 1.462 = $5.62 Mil.
Total Receivables was $12.63 Mil.
Revenue was 13.422 + 12.672 + 8.876 + 9.396 = $44.37 Mil.
Gross Profit was 10.005 + 9.14 + 6.358 + 6.727 = $32.23 Mil.
Total Current Assets was $42.08 Mil.
Total Assets was $166.08 Mil.
Property, Plant and Equipment(Net PPE) was $6.12 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $23.62 Mil.
Total Current Liabilities was $12.72 Mil.
Long-Term Debt & Capital Lease Obligation was $15.24 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(16.194 / 60.63) / (12.633 / 44.366)
=0.267095 / 0.284745
=0.938

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(32.23 / 44.366) / (44.835 / 60.63)
=0.726457 / 0.739485
=0.9824

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (79.79 + 10.579) / 216.465) / (1 - (42.081 + 6.119) / 166.077)
=0.582524 / 0.709773
=0.8207

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=60.63 / 44.366
=1.3666

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 6.119)) / (0 / (0 + 10.579))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(30.886 / 60.63) / (23.622 / 44.366)
=0.509418 / 0.532435
=0.9568

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.913 + 19.191) / 216.465) / ((15.242 + 12.724) / 166.077)
=0.097494 / 0.168392
=0.579

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(9.708 - 0 - 5.623) / 216.465
=0.018871

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Xvivo Perfusion AB has a M-score of -2.06 suggests that the company is unlikely to be a manipulator.


Xvivo Perfusion AB Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.